Esophageal Carcinosarcoma Comprising of Undifferentiated Pleomorphic Sarcoma and Squamous Cell Carcinoma: A Case Report

2021 ◽  
Author(s):  
Ziyao Fang ◽  
Shu Pan ◽  
Chun Xu ◽  
Sheng Ju ◽  
Ziqing Shen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Thoracic Surgery ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Polypoid Lesion ◽  
Clinical Manifestations ◽  
Undifferentiated Pleomorphic Sarcoma ◽  
Esophageal Carcinosarcoma ◽  
Pleomorphic Sarcoma ◽  
Vats Esophagectomy

Abstract Introduction: Esophageal carcinosarcoma (ECS) is a rare malignant tumor that often presents as an intraluminal polypoid lesion in the esophageal lumen. Herein we present a case diagnosed as esophageal carcinosarcoma and treated with esophagectomy.Case presentation: A 68-year-old male patient was presented to the thoracic surgery department complaining of dysphagia for about three months. He was diagnosed with ECS and underwent uniport video-assisted thoracic surgery (VATS). Based on the histopathological reports, the patient was finally diagnosed as ECS, clinical T1bN0M0, pathological stage I. 11 days after the surgery, the patient was discharged from the hospital without experiencing any complications.Conclusion: Carcinosarcoma was first described by Virchow in 1865 as a rare malignant neoplasm. The clinical manifestations of ECS includes dysphagia, chest pain and weight loss. IHC analysis indicates carcinoma and the sarcoma occurred independently. Complete resection of the esophagus with lymphadenectomy of locoregional nodes is still recommended as the best potentially curative treatment. For the prognosis of ECS compared to (ESCC), there is a controversy. Here, we reported a case of ECS comprising of squamous cell carcinoma in situ and undifferentiated pleomorphic sarcoma underwent uniport VATS esophagectomy with no serious complications, which indicate that VATS esophagectomy could be applied to ECS patients.

scholarly journals Ureteral urothelial carcinoma with squamous cell carcinoma and sarcomatoid carcinoma differentiation: a case report

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Shangqing Ren ◽  
Hualin Feng ◽  
Yige Bao ◽  
Yi Wei ◽  
Yong Ou ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Standard Treatment ◽  
Clinical Manifestations ◽  
Sarcomatoid Carcinoma ◽  
Upper Urinary Tract ◽  
Malignant Tumours

Abstract Background Upper urinary tract urothelial carcinoma (UTUC) with multiple pathological types is extremely rare in the clinic, but the recurrence rate and mortality these patients are high. At present, there is no standard treatment for such cases. Case presentation We reported a case of ureteral urothelial carcinoma with squamous cell carcinoma and sarcomatoid carcinoma differentiation and rapid ileal metastasis and reviewed the literature related to different pathological types of upper urinary tract tumours to explore the diagnosis, treatment and prognosis characteristics of the disease, enhance our understanding of its clinical manifestations and history of evolution and provide guidance for avoiding missed diagnosis and misdiagnosis. Conclusion There is no standard treatment for urinary malignant tumours with multiple pathological types; radical surgery is considered a suitable choice. Chemotherapy, targeted drug therapy and immunotherapy may be beneficial to the survival of patients. In short, these patients have a high risk of recurrence and metastasis and a poor prognosis.

scholarly journals Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma

Medicine ◽  
2018 ◽  
Vol 97 (41) ◽  
pp. e12796
Author(s):  
Kenji Tsuchihashi ◽  
Shuji Arita ◽  
Minako Fujiwara ◽  
Kazuhide Iwasaki ◽  
Atsushi Hirano ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Squamous Cell ◽  
Esophageal Carcinosarcoma ◽  
Carcinoma Squamous Cell

scholarly journals Notch Intracellular Domain (NICD) Expression and Clinical Manifestations of Second Primary Tumor at Esophagus in Patients with Head and Neck Squamous Cell Carcinoma

2019 ◽  
Vol Volume 12 ◽  
pp. 11175-11181
Author(s):  
Tauangtham Anekpuritanang ◽  
Warut Pongsapich ◽  
Tanasarun Watcharadilokkul ◽  
Premyot Ngaotepprutaram ◽  
Paveena Pithuksurachai ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Clinical Manifestations ◽  
Neck Squamous Cell Carcinoma ◽  
Second Primary ◽  
Second Primary Tumor ◽  
Notch Intracellular Domain

Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2558-2558
Author(s):  
Ozgur Karakuzu ◽  
Apostolia Maria Tsimberidou ◽  
Veronica R. Holley ◽  
Abha Adat ◽  
Sapna Pradyuman Patel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Unknown Primary ◽  
Phase 2 ◽  
Carcinoma Of Unknown Primary ◽  
Second Stage ◽  
Pleomorphic Sarcoma ◽  
Myxoid Sarcoma

2558 Background: BXCL701 is an oral competitive inhibitor of dipeptidyl peptidases (DPPs), primarily DPP8/9, which triggers the inflammasome to alert and prime immune cells, leading to induction of IL-18 and IL-1ß. BXCL701 therefore, can induce an innate immune reaction and tumor inflammation, bridging between innate and adaptive immunity, potentially leading to synergistic anticancer activity when combined with PD-1 antibody pembrolizumab. Methods: This is a phase 2, open-label, single-center study (NCT04171219) of oral BXCL701 0.3 mg BID on days 1-14 and intravenous pembrolizumab 200 mg on day 1 of a 21-day cycle with a safety lead-in to evaluate RECIST/iRECIST response rate in patients with advanced solid cancers. After confirming safety and dose limiting toxicities (DLT) in the first 6 patients, additional patients are being enrolled to an immune checkpoint inhibitors (iCPI) naïve cohort and iCPI pretreated cohort. Each cohort is planned to enroll 9 patients in the first stage, and if a partial (PR) or complete response (CR) is observed the cohort is expanded to a total of 17 patients in the second stage. The treatment is considered promising if at least 3 PRs or CRs are observed in a cohort of 17 patients. Results: As of February 11, 2021, 16 patients were treated; 5 patients (prostate cancer, endometrial cancer, liposarcoma, basal cell carcinoma, squamous cell carcinoma of unknown primary) were enrolled in the iCPI naïve cohort and 11 patients (leiomyosarcoma [2], squamous cell carcinoma of unknown primary, triple negative breast cancer, uveal melanoma, melanoma, uterine myxoid sarcoma, pleomorphic sarcoma, colorectal cancer, anaplastic astrocytoma, prostate cancer) were enrolled to iCPI pretreated cohort. Among all 16 patients, there was 1 episode of grade 4 hypotension (recovered) and 1 episode of grade 5 hypotension attributed to BXCL701, which resulted in implementation of risk-mitigation strategies such as gradual dose escalation and blood pressure monitoring. In the CPI naïve cohort, of 4 patients with available imaging, 1 had a PR (microsatellite stable endometrial cancer [-62%]) and 1 durable stable disease (SD -10%, basal cell carcinoma on therapy for 6+ months). In the CPI pretreated cohort, of 9 patients with available imaging, 1 had a PR (-31%, uveal melanoma) and 3 durable SD (-22%, pleomorphic sarcoma on therapy for 8+ months; +4%, squamous cell carcinoma of unknown primary on therapy for 6 months; +5%, uterine myxoid sarcoma on therapy for 6 months). Conclusions: BXCL701 in combination with pembrolizumab demonstrated encouraging signals of activity in selected difficult-to-treat cancers. Prespecified efficacy endpoints were met in the first stage and both cohorts will proceed to second-stage of the study Clinical trial information: NCT04171219.

Sign in / Sign up

Export Citation Format

Share Document